PhRMA/NCI initiative
Executive Summary
The Pharmaceutical Research & Manufacturers of America and the National Cancer Institute will share costs for a $6 mil., two-year pilot program that seeks models to increase patient participation in Phase I and Phase II clinical trials. Five to eight cancer centers will be selected to participate; proposals are due Sept. 24. The participating PhRMA members are: GlaxoSmithKline, Aventis, Lilly, Bristol-Myers Squibb and Novartis...